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Abstract
Introduction: The atrial fibrillatory rate is a potential biomarker in the study of
antiarrhythmic drug effects on atrial fibrillation (AF). The purpose of this study was to
evaluate whether dose‐dependent changes in the atrial fibrillatory rate can be
monitored on surface electrocardiography (ECG) following treatment with dofetilide,
ranolazine, and a combination of the two in an acute model of AF in horses.
Methods and Results: Eight horses were subjected to pacing‐induced AF on 4
separate days. Saline (control), dofetilide, ranolazine, or a combination of
dofetilide and ranolazine was administered in four incremental doses. Atrial
fibrillatory activity was extracted from surface ECGs using spatiotemporal QRST
cancellation. The mean atrial fibrillatory rate before drug infusion was
297 ± 27 fpm. Dofetilide reduced the atrial fibrillatory rate following the infusion
of low doses (0.89 µg/kg, P < 0.05) and within 5 minutes preceding cardioversion
(P < 0.05). Cardioversion with ranolazine was preceded by a reduction in the
atrial fibrillatory rate in the last minute (P < 0.05). The combination of drugs
reduced the atrial fibrillatory rate in a similar manner to dofetilide used alone. A
trend toward a lower atrial fibrillatory rate before drug infusion was found
among horses cardioverting on low doses of the drugs.
Conclusion: The atrial fibrillatory rate derived from surface ECGs showed a
difference in the mode of action on AF between dofetilide and ranolazine.
Dofetilide reduced the atrial fibrillatory rate, whereas ranolazine displayed a
cardioverting mechanism that was distinct from a slowing of the fibrillatory
process.
© 2019 The Authors. Journal of Cardiovascular Electrophysiology Published by Wiley Periodicals, Inc.
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1 | INTRODUCTION
Pharmacological treatment is important in the control of atrial fibrillation
(AF) and restoration of sinus rhythm. However, the antiarrhythmic drugs
currently available display varying efficacy and most, if not all, can cause
severe adverse reactions.1 This has created an emerging interest in
combining two antiarrhythmic drugs to create a synergistic effect,
thereby increasing efficacy while potentially avoiding toxicity through the
use of lower doses of each drug.2 Our group, recently studied the
antiarrhythmic effects of combining dofetilide and ranolazine in a model
of induced AF in horses and found that the combination increased the
efficacy of the drugs.3 Dofetilide is a Class III antiarrhythmic drug that
selectively blocks the rapidly activating delayed rectifier potassium
current (IKr) and is known to increase the QT interval and the risk of
ventricular arrhythmias.1 Ranolazine blocks the late sodium current (INa,
late) and in higher doses also IKr. Furthermore, ranolazine potently blocks
the peak sodium current (INa,peak) in the atria.
4,5
In recent years, substantial attention has been paid to monitoring the
atrial activity on surface electrocardiography (ECG) during AF. Measuring
the ECG‐derived atrial fibrillatory rate (AFR) is a noninvasive method and
has been used to study the electrical remodeling that occurs during
AF.6–8 Furthermore, it has been proposed that AFR can be used to assess
antiarrhythmic drug effects9–12 and may predict the likelihood of drug‐
induced cardioversion.7 The alterations in atrial activity evident on the
surface ECG following administration of a number of antiarrhythmic
drugs (including dofetilide and ranolazine) have been studied,9,10,13–15 yet
no such studies on the use of combination therapies are available.
The horse has been suggested as a model of human AF, as, like
humans, horses develop both lone AF and AF as a consequence of
underlying structural heart disease.16 Experimental induction of AF is
easily performed in horses and has been used in several pharmaco-
logical studies.3,17–19 Furthermore, it has recently been shown that
AFR dynamics in horses with experimentally induced AF resemble
AFR dynamics in humans with paroxysmal AF and that flecainide
administration has a very similar effect on AFR in the two species.20
In the present study, we aimed to investigate the effects of
dofetilide and ranolazine, both alone and in combination, on AFR in a
model of acutely induced AF in horses.
2 | MATERIALS AND METHODS
ECGs obtained from eight standardbred horses (body weight 492±32 kg,
age 8.9 ± 3.4 years; five mares and three geldings) were included in the
study. Data were collected from previously published experiments and
the design of the study has, therefore, been described.3 Furthermore, five
ECGs from the control experiments were previously used for studying
AFR dynamics in horses.20 In brief, all horses were subjected to four
procedures with a 1‐week washout period in between. All procedures
were performed on standing nonsedated horses restrained in a stock.
During each procedure, the horses were instrumented with two
multipolar steerable nonfixative electrodes (Inquiry Steerable Diagnostic
Catheter, 6 Fr/110 cm; St. Jude Medical, St. Paul, MN) in the right atrium;
one for pacing and one for obtaining an atrial electrogram, and AF was
induced by burst‐pacing with 50Hz for 4 to 6 seconds. Once an episode
of AF with a duration of over 15minutes was observed, drug treatment
was initiated with either saline (NaCl 9mg/mL; B. Braun, Melsungen,
Germany), dofetilide (Catalog No. 3757; Tocris Bioscience, R&D Systems,
Abingdon, UK), ranolazine (Catalog No. 3118; Tocris Bioscience, R&D
Systems), or a combination of dofetilide and ranolazine. All drugs were
administered over four stages with 20minutes and a threefold increase in
the total dose between each stage being observed. The total dose of
dofetilide was 8.00 µg/kg and the total dose of ranolazine was 2.40mg/
kg. Saline was administered at a total dose of 0.20mL/kg as this most
closely resembled the volume of the drugs used. In the combination
procedure, ranolazine was given at an identical dose as when used alone
and 0.89 µg/kg of dofetilide was given with the first dose of ranolazine.
All solutions were administered intravenously at a rate of 0.0125mL/kg/
min. All horses received all four doses regardless of the time of
cardioversion. Horses that cardioverted within 30minutes of the last
dose being administered were classified as responders as opposed to the
nonresponders that did not cardiovert within this time period.
The study was approved by the local ethical committee at the
Department of Veterinary Clinical Sciences, University of Copenhagen
and the Danish Animal Experiments Inspectorate (license number 2012‐
15‐2934‐00198), and was performed in accordance with the European
Commission Directive 86/609/EEC.
2.1 | ECG recordings and analysis
A surface ECG was obtained throughout each procedure using a Holter
unit (Televet, Maarslev, Denmark).17 Identical recordings were obtained
simultaneously using LabChart 7 software (ADInstruments, Oxford, UK).
The digital ECG from each AF episode from induction to cardioversion
was exported and processed using AFR Tracker software (CardioLund
Research AB, Lund, Sweden) to obtain the AFR and exponential decay
(ED), which is a measure of organization of the rhythm.10 The processing
method using spatiotemporal QRST cancellation has been described
elsewhere6,8 and was previously used to analyze equine ECGs.20 In this
study, the AFR represents the average rate for 1‐minute intervals.
2.2 | Data analysis
All data are presented as mean ± SD. All analyses were performed using
GraphPad Prism 5 software (GraphPad Software, San Diego, CA), with
P ≤0.05 considered to be significant. All mean AFR and ED values are a
mean of five consecutive minutes unless stated otherwise. The mean
AFR and ED before treatment were compared for the four different
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procedures using a one‐way repeated‐measures analysis of variance
followed by a Bonferroni posttest for pairwise comparisons. A moving
median of five consecutive minutes was used for graphical illustration of
the AFR for each individual horse during the different procedures. The
mean AFR was compared before and after administration of each dose
using paired t tests. Similarly, the mean ED was compared before and
after administration of the drug doses. Using unpaired t tests, the mean
AFR before drug infusion was compared for responders and non-
responders in the control procedures as well as for animals cardiovert-
ing before and following the third dose in the dofetilide and ranolazine
procedures.
3 | RESULTS
As previously shown,3 two out of eight horses cardioverted during the
control procedures, whereas the remaining six horses remained in AF
for more than 1 hour following the last saline administration. Seven of
the eight horses restored sinus rhythm during dofetilide treatment,
eight during ranolazine treatment, and seven during the administration
of the two drugs combined. An example of ECG recordings from each of
the three drug procedures is given in Figure 1.
The mean AFR before drug treatment (including all procedures
performed on all horses) was 297 ± 27 fpm and no differences were
found in the mean AFR before drug treatment among the four
procedures (control, dofetilide, ranolazine, and the combination of
dofetilide and ranolazine; P = 0.29). Development of the AFR during
the different drug treatments is illustrated for each horse in Figures 2
to 5. The mean ED before drug treatment was not different among
the four procedures (P = 0.66).
3.1 | Control
In the graphical illustration of AFR during the control procedures, it is
seen that the AFR of the nonresponders remained relatively stable
throughout the procedures (Figure 2). This is demonstrated by
comparisons in Table 1, finding no differences in mean AFR before
and after each of the four saline infusions. For the two horses
cardioverting after the first saline administration (ID1 and ID6), AFR
started to decrease in 5 and 11minutes, respectively, before the
administration was initiated (Figure 2).
The mean ED before drug infusion was 1.34 and there were no
differences found when comparing ED before and after the four saline
doses.
3.2 | Dofetilide
Administration of a very low dose of dofetilide (dose 1, 0.30 µg/kg)
was not accompanied by any consistent decrease in AFR during or
following drug infusion, as visualized in Figure 3 and substantiated in
Table 1. The horse that cardioverted after dose 1 (ID3) presented
with a decreasing AFR trend that started 2minutes before drug
infusion. A decrease in mean AFR was evident after dose 2 of
dofetilide (total dose received 0.89 µg/kg; Table 1). However, this
decrease was not apparent in all horses (ID8). In ID2 and ID7 the
decrease started 7 and 3minutes before drug administration,
respectively (Figure 3). A decrease in AFR initiated during drug
infusion was consistently observed in five horses (ID1/2/4/5/8) that
received dose 3 (total dose received 2.67 µg/kg) while in AF, with
AFR stabilizing at a lower level (ID2/4/5/8) or returning to the
preinfusion level (ID1) at the end of dose 3 infusion (Figure 3 and
Table 1). A further decrease in AFR was seen in the nonresponder
(ID8) following dose 4 but this was not followed by a restored sinus
rhythm (total dose received was 8.00 µg/kg; Figure 3).
A comparison of the mean AFR before the first drug infusion and
the mean AFR in the 5minutes leading up to cardioversion for all
responders revealed a significant decrease in AFR. This was also the
case for the last minute before cardioversion (Table 2). Studying the
decrease in AFR in the individual animals it was found that horses
with an AFR less than 300 fpm before the first drug infusion showed
F IGURE 1 Electrocardiographic examples from drug procedures. ECG recordings from the same horse before drug infusion and during
cardioversion in all three drug procedures; dofetilide (A), ranolazine (B), and the combination of dofetilide and ranolazine (C). ECG,
Electrocardiography
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a decrease in AFR leading up to cardioversion of between 14% and
24%. In horses with an AFR of above 300 fpm before drug infusion,
the reduction was between −8% and 12%.
The mean ED before drug infusion was 1.40. No differences were
found between ED before and after the four doses and neither when
comparing ED before dofetilide infusion to the mean ED in the
5minutes or last minute leading up to cardioversion.
3.3 | Ranolazine
There was no distinct decrease in AFR following drug infusions in
the ranolazine procedures for the majority of the horses (Figure 4).
This finding corresponds to the lack of change in mean AFR before
and after the first and second drug infusions presented in Table 1.
In ID2, ID3, and ID8, however, there was a decrease in AFR related
to dose 3 (total dose received 0.94 mg/kg), and to dose 4 (total
dose received 2.40 mg/kg) in ID2 and ID8 (Figure 4 and Table 1).
When comparing the mean AFR before the first drug infusion to
the mean AFR in the 5minutes leading up to cardioversion, no
decrease was found. Conversely, AFR was significantly reduced in the
last minute leading up to cardioversion (Table 2). Comparing the AFR
before drug infusion to the AFR before cardioversion did not reveal
any differences in reduction of the AFR between horses with an
initial AFR above or below 300 fpm.
The mean ED before drug infusion was 1.39. No differences were
found between ED before and after the four doses or between ED
F IGURE 2 Atrial fibrillatory rate (AFR)
during control procedures. Each graph
illustrates the moving‐median AFR in
individual horses during the control
procedures with time on the x‐axis and
fibrillations per minute (fpm) on the y‐axis.
The dotted lines mark the start and end of
the drug infusions
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before ranolazine infusion and the mean ED in the 5minutes or last
minute leading up to cardioversion.
3.4 | Combination therapy
A more (ID1/3/4) or less (ID2/6) pronounced decrease in AFR
following the first combination dose of dofetilide (0.89 µg/kg) and
ranolazine (0.104mg/kg) was seen in five out of eight horses and in
another animal (ID5), this decrease was initiated 3minutes before
drug administration (Figure 5 and Table 1). These findings were not
consistent in ID7 and ID8 (Figure 5). In the horse that received all
four drug doses while in AF (ID2), a slight decrease in AFR was seen
in relation to all dose administrations.
The mean AFR of the 5minutes leading up to cardioversion for
the responders was lower when compared with the mean AFR before
the first combination infusion. Similarly, AFR was lower in the last
minute before cardioversion (Table 2). Comparing the reduction in
AFR between horses displaying an AFR below and above 300 fpm
before drug infusion did not reveal any differences.
The mean ED before the first drug infusion was 1.36. No differences
were found between ED before and after the four doses of combination
therapy. However, the ED in the 5minutes and in the last minute
leading up to cardioversion was significantly different from the ED
before the first drug infusion (P =0.019 and 0.039, respectively).
3.5 | AFR as a predictive measure
No significant differences were found between responders and
nonresponders in the control procedures when comparing the mean
AFR before drug infusion. The responders had an AFR of 265 ± 43 fpm,
whereas AFR for the nonresponders was 300 ± 9 fpm (P =0.45). For the
dofetilide procedures, AFR was 298 ± 41 and 325 fpm for the
responders and nonresponder, respectively. As ranolazine terminated
AF in all animals, a comparison could not be made with this treatment.
In the combination procedures, AFR was 288 ± 17 and 308 fpm for the
responders and nonresponder, respectively.
In the dofetilide and ranolazine procedures, the mean AFR before
drug infusion was compared for animals cardioverting before and
following dose 3 to test AFR as a predictor of the dose required for
cardioversion. In the dofetilide procedures, animals that cardioverted
before (n = 3) and following (n = 5) dose 3 had a mean AFR of
278 ± 30 and 315 ± 39 fpm, respectively (P = 0.21). In the ranolazine
procedures, the mean AFR was 283 ± 34 fpm for animals that
cardioverted before dose 3 (n = 3) and 316 ± 16 fpm for those that
cardioverted after dose 3 (n = 5; P = 0.10).
4 | DISCUSSION
This study is the first to assess the effect of ranolazine, both on its own
and in combination with dofetilide, on the AFR retrieved from surface
ECG preceding cardioversion. A clear slowing of the atrial fibrillatory
process before cardioversion was observed with dofetilide alone and inT
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F IGURE 3 Atrial fibrillatory rate (AFR)
during dofetilide procedures. Each graph
illustrates the moving‐median AFR in
individual horses during the dofetilide
procedures with time on the x‐axis and
fibrillations per minute (fpm) on the y‐axis.
The dotted lines mark the start and end of
the drug infusions
TABLE 2 Atrial fibrillatory rate before drug infusion and at cardioversion in responders
Before/last
AFR before AFR last 5minute AFR last 1minute 5minutes (P) 1 minute (P)
Dofetilide (n = 7) 298 ± 41 286 ± 50 276 ± 45 0.02* 0.01*
Ranolazine (n = 8) 304 ± 28 299 ± 29 276 ± 37 0.37 0.02*
Combination (n = 7) 288 ± 17 269 ± 21 254 ± 20 0.04* 0.01*
Abbreviations: AFR, atrial fibrillatory rate; AFR before, average of AFR 5minutes before drug infusion; AFR last 1minute: the last AFR value before
cardioversion; AFR last 5 minutes: average of AFR 5minutes before cardioversion.
Values are given in fibrillations per minute ± SD.
*Statistical significance (P < 0.05).
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combination with ranolazine, yet this mechanism was not consistently
found with the use of ranolazine alone.
4.1 | Use of AFR to monitor antiarrhythmic drug
effects
Previous studies looking into the effects of dofetilide on the atrial
fibrillatory process have found a significant decrease in AFR after
drug administration.13,21 These findings are consistent with the
present study, where dofetilide administration led to a dose‐
dependent AFR decrease: no measurable effect following dose 1, a
4.5% reduction in AFR following dose 2 and an 8.0% reduction in AFR
following dose 3 (Table 1). Like other potassium channel blockers,
dofetilide is known to increase atrial refractoriness.1 However, no
changes in the atrial effective refractory period were found following
dofetilide administration in horses,3 which could call into question
the functional role of IKr in equine atria. In contrast, AFR modification
following dofetilide administration indicates that IKr does indeed play
a role in the equine atria, as blocking the current decreases AFR.
Furthermore, it appears that dofetilide could display negative
use‐dependence in horses as reported in other species22 as we saw
a larger reduction in AFR in horses with a slower initial AFR. This
F IGURE 4 Atrial fibrillatory rate (AFR)
during ranolazine procedures. Each graph
illustrates the moving‐median AFR in
individual horses during the ranolazine
procedures with time on the x‐axis and
fibrillations per minute (fpm) on the y‐axis.
The dotted lines mark the start and end of
the drug infusions
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relationship is well described for IKr blockers, in general but has not
previously been studied in horse atria.
In contrast with dofetilide, ranolazine infusion in low doses was
associated with barely measurable effects on AFR in the majority
of animals. Conversely, a decrease was seen following higher doses
of ranolazine. In a study by Black‐Maier et al15 ranolazine was
found to decrease the dominant atrial fibrillatory wave frequency
in AF patients, which resembles our findings with the higher doses
of ranolazine. When analyzing AFR during the time preceding
cardioversion, a reduction was only seen during the last minute
before cardioversion, while dofetilide administration was asso-
ciated with a nearly immediate and more pronounced reduction in
AFR. This indicates a difference between the two antiarrhythmic
drugs in the effect on atrial electrophysiology and in the way they
terminate AF. Ranolazine blocks INa,late and IKr but also has a
blocking effect on INa,peak in the atria.
4,5 Dofetilide is reported to
be a selective IKr channel blocker when applied acutely,
1 while
chronic exposure may increase INa,late.
23 One can speculate that
the reduction in AFR following high‐dose ranolazine administra-
tion (which mimics AFR behavior induced by dofetilide) may reflect
the increased IKr blockade. There is conflicting clinical experience
on the effect of other combined ion channel blockers on AFR
during AF. The combined potassium and sodium blocker AZD7009
has been found to significantly reduce AFR,9 whereas bepridil,
F IGURE 5 Atrial fibrillatory rate (AFR)
during combination procedures. Each
graph illustrates the moving‐median AFR in
individual horses during the combination
procedures, with time on the x‐axis and
fibrillations per minute (fpm) on the y‐axis.
The dotted lines mark the start and end of
the drug infusions
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which has sodium, potassium, and calcium channel blocking
properties did not reduce AFR significantly.24
When dofetilide and ranolazine were combined, AFR was
significantly reduced in 5minutes leading to cardioversion, resem-
bling the effect when dofetilide was used alone. This effect was
expected, as dose 1 of dofetilide in the combination procedures
(0.89 µg/kg) was identical to the dofetilide dose the horses had
received following the second infusion in the dofetilide‐only
procedures, in which a clear trend of AFR reduction was seen in
the majority of horses (Figure 3). Interestingly, the reduction in AFR
did not show any relation to the initial AFR of the individual horses
suggesting that the addition of ranolazine counterbalances the
reverse use‐dependence of dofetilide. Furthermore, the combination
of drugs resulted in a decreased ED before cardioversion reflecting a
greater organization of the AF during this time. This finding may be
part of the explanation of the increased antiarrhythmic effects of the
combination of dofetilide and ranolazine.
In a study by Wijffels et al25 the antiarrhythmic effects of Classes I
and III antiarrhythmic drugs were not explained by a prolongation of
the atrial wave length (wave length = refractory period × conduction
velocity26) but rather by a widening of the temporal excitable gap,
which is the difference between the atrial fibrillatory cycle length and
the refractory period. We have only studied the atrial refractoriness
after cardioversion to sinus rhythm but did not find any significant
prolongation.3 An explanation for the antiarrhythmic effects could,
therefore, be an increase in the temporal excitable gap because the
atrial fibrillatory cycle length is increased (the AFR is decreased) to a
smaller or larger degree by all the drugs in our study. However, we
would need to measure the conduction velocity and possible
alterations following drug infusions to be able to conclude whether
the wave length and path length were altered. The difference between
these two parameters reflects the spatial excitable gap, which was
found to increase significantly with the use of D‐sotalol (Class III) but
not flecainide (Class I) in goats.25
4.2 | Prediction of drug doses for cardioversion
In a study by Bollmann et al7 on the effects of Class III antiarrhythmic
drug ibutilide, the baseline fibrillatory rate was lower in patients that
cardioverted solely on antiarrhythmic therapy than in patients who
failed to cardiovert on drugs and required electrical cardioversion. In
contrast, Raygor et al13 found no such difference in their study on
dofetilide and in a study of another Class III antiarrhythmic
compound vernakalant, no difference could be found between the
baseline AFR of responders and nonresponders.14 Similar findings
were observed in a study of AZD7009.9 The present study addressed
the possible difference between horses requiring lower or higher
doses of dofetilide or ranolazine for cardioversion by comparing the
mean AFR before drug infusion for horses cardioverting on a low
dose and for horses not cardioverting, or cardioverting on higher
doses of the studied drugs. We could not confirm any significant
difference in the mean AFR before drug infusion between these two
groups but the AFR values were lower in animals exhibiting a
restored sinus rhythm on the lower doses. However, due to the small
sample size, a definitive conclusion on the prognostic value of AFR
for predicting the drug effect cannot be drawn.
4.3 | Spontaneous cardioversion in the horse model
All horses in the present study cardioverted spontaneously, if not by
drug intervention. Hesselkilde et al20 found AFR in horses with
induced AF to be comparable to AFR in humans with paroxysmal AF,
suggesting similar AFR cut off values for spontaneous cardioversion
around 350 fpm.27 In addition, the horses with induced AF had lower
AFR values compared to horses with spontaneous persistent AF.20
The mean AFR before drug infusion in the present study was
297 ± 27 fpm, so spontaneous cardioversion was expected. A study of
ten horses showed that acutely induced AF with a duration of over
15minutes will terminate after more than 1 hour,18 and another
study of three horses found the time to cardioversion of AF episodes
of more than 15minutes to be 5.8 ± 3.2 hours.17 In the present study,
two horses cardioverted spontaneously (following saline administra-
tion) after 20minutes of AF, whereas six horses remained in AF for
more than 2.5 hours once an AF episode of 15minutes or longer was
obtained. Despite a reduction in AFR that started before drug
infusion in the two early cardioverters and a difference in the mean
AFR before drug infusion of 35 fpm between the two groups, no
statistical significance was reached. The graphical behavior of AFR at
the beginning of an acutely induced AF episode may, however, be an
indicator of the length of the AF episode. In humans, it was found
that AF episodes that terminated spontaneously within 5minutes
reached a lower peak fibrillation frequency than AF episodes of a
longer duration.7
4.4 | Study limitations
The number of animals used in the present study was small and the
statistical significance should be evaluated with caution. As a
consequence, we have used graphical illustrations to support the
findings of the study.
In our study set‐up, we were unable to assess the conduction
velocity during AF, which could have allowed us to determine the
wave length and path length as well as the spatial excitable gap
during AF. Consequently, we are only able to speculate on the
mechanisms behind the antiarrhythmic effects of dofetilide and
ranolazine alone and in combination in induced AF in horses. To asses
this parameter, a more invasive study set‐up is required involving
implantation of several electrodes as previously done in, for example,
dogs and goats28,29 or by using a mapping system to secure a stable
and similar position of electrodes in all horses.
If the half‐life of ranolazine is short (currently unknown in horses),
the dosing regimen, which had a duration of over 1.3 hours, may have
been problematic. The desired plasma levels may not have been reached
and a measure of plasma levels would, therefore, be very valuable. The
doses infused have, however, previously been shown to cardiovert
horses in AF faster than controls3 and we, therefore, assume that the
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plasma levels of ranolazine should have reached levels high enough to
affect the AFR if this was the mode of action.
5 | CONCLUSION
Termination of AF after ranolazine administration followed a very rapid
reduction in AFR immediately before rhythm restoration, which suggests
that ranolazine AF‐cardioverting mechanisms are not directly related to
the slowing of the fundamental atrial fibrillatory frequency, limiting the
ability of surface ECG to monitor ranolazine effects during AF. In
contrast, however, our data support the use of surface ECG for
monitoring the antiarrhythmic effects of dofetilide, which decreased
AFR in a dose‐dependent manner, even in low doses. Overall, this study
has demonstrated the differences in the mode of action on AF between
different antiarrhythmic drugs, detected using a noninvasive approach
and our results further support the use of ECG‐derived AFR monitoring
for the assessment of antiarrhythmic drug effects during AF.
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